Piper Sandler analyst David Amsellem initiated coverage of Axsome Therapeutics with a Neutral rating and $75 price target. Though he sees much to like about Auvelity in both major depressive disorder nd Alzheimer’s associated agitation, the analyst is cautious on Axsome shares in part given the heavy spend needed to support a brand antidepressant in a heavily genericized, promotion-intensive space. Beyond that, his caution is also a function of doubts regarding the extent to which the company’s other opportunities will be major contributors.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AXSM:
- Axsome Therapeutics named Top Pick for first half of 2023 at BTIG
- Axsome Therapeutics price target raised to $98 from $62 at BTIG
- AXSOME call volume above normal and directionally bullish
- Axsome Therapeutics presents data on EVOLVE open-label trial of AUVELITY
- Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
